Nancy Lambrianides

CSMM Academic Staff

Current Position

Post Doctoral Fellow, Neurology Clinic C, The Cyprus Institute of Neurology & Genetics

Education

MSc Molecular Medicine, University College London 2001
PhD Clinical Medicine, University College London 2006

 

Academic Appointments:

2007- 2011: Research Associate, Centre of Rheumatolgy, Department of Medicine, University College London
2011-2012: Research associate, Department of Civil and Environmental Engineering, University of Cyprus
2012-today: Faculty Associate, The Cyprus School of Molecular Medicine

 

 

Research Interests

Her research interests have been focused on how antibodies lead to pathogenicity. The goal of this research would be to design a more effective and targeted therapy to block the effects of these antibodies in patients with autoimmune diseases.

Biography

Dr Nancy Lambrianides received her MSc degree in Molecular Medicine from University College London in 2001 and her PhD from University College London, in 2006 where she was also appointed as postdoctoral associate until 2011. She has published over 20 articles, in peer-reviewed journals and was the principal investigator for a project funded by the Hellenic Academy of Neuroimmunology. She have acted as the primary supervisor of one PhD and 2 MSc who have successfully completed their studies at The Cyprus School of Molecular Medicine as well as co-supervising several students while working at University College London. Her main research interests include the pathogenesis of autoantibodies in autoimmune diseases and how to design a therapy to block the effects of these antibodies where direct translational benefits for patients will be achieved. She serves as a reviewer for several scientific journals.

 

Selected Publications:

  1. Filippidou N, Krashias G, Pericleous C, Rahman A, Ioannou Y, Giles I, Demetriou C, Anatolitou A, Christodoulou C, Pantzaris M, Lambrianides A.  The association between IgM and IgG antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. Mol Immunol. 2016 Jul;75:161-7.
  2. Ripoll VM, Lambrianides A, Pierangeli SS, Poulton K, Ioannou Y, Heywood WE, Mills K, Latchman DS, Isenberg DA, Rahman A, Giles IP. Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.Blood. 2014 Dec 11;124(25):3808
  3. Lambrianides A, Turner-Stokes T, Pericleous C, Ehsanullah J, Papadimitraki E, Poulton K, Ioannou Y, Mackie I, Chen P, Latchman DS, Isenberg DA, Rahman A, Giles IP. Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in haemostasis. Arthritis Rheum. 2011 Nov;63(11):3512-21. 
  4. Lambrianides A, Carroll CJ, Pierangeli SS, Pericleous C, Branch W, Rice J, Latchman DS, Townsend P, Isenberg DA, Rahman A, Giles IP. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol. 2010 Jun 15;184(12):6622-8.
  5. Lambrianides A, Giles IP. Use of monoclonal antibodies to dissect specificity and pathogenesis. Lupus. 2010 Apr;19(4):359-64.
  6. O’Neill S, Giles I, Lambrianides A, Manson J, D’Cruz D, Latchman DS, Isenberg DA, Rahman A. Antibodies to apolipoprotein A1, high density lipoprotein and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2010 Mar;62(3):845-54.
  7. Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JC, Isenberg DA. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2007.
  8. Lambrianides A, Giles I, Ioannou Y, Mason L, Jessica M, Latchman DS, Isenberg DA, Rahman A. Substitution of a single arginine residue alters the binding properties of a human monoclonal antibody to multiple clinically relevant antigens. Arthritis Rheum 2007; 56 (7): 2392-401. 
  9. Giles I, Lambrianides N, Pattni N, Faulkes D, Latchman DS, Chen P, Chukwuocha R, Pierangeli S, Isenberg DA, Rahman A. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006; 177 (3): 1729-36.
  10. Mason LJ*, Lambrianides A*, Haley JD, Manson JJ, Latchman DS, Isenberg DA, et al. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res Ther 2005; 7 (5):R971-83.
winner aashe copernicus